Corcept Therapeutics Inc. | Ownership
Companies that own Corcept Therapeutics Inc.
BlackRock Fund Advisors
13,065,675
11.26%
1,135,242
0.01%
06/30/2018
Federated Global Investment Management Corp.
11,920,108
10.27%
-766,619
1.28%
06/30/2018
The Vanguard Group, Inc.
10,107,790
8.71%
1,530,441
0.01%
06/30/2018
Ingalls & Snyder LLC
7,316,990
6.31%
499,450
4.82%
06/30/2018
Consonance Capital Management LP
4,628,417
3.99%
-560,000
3.72%
06/30/2018
Renaissance Technologies LLC
4,345,400
3.74%
-453,100
0.07%
06/30/2018
SSgA Funds Management, Inc.
2,908,557
2.5%
-228,147
0%
06/30/2018
Acadian Asset Management LLC
2,786,241
2.4%
-528,328
0.11%
06/30/2018
Invesco Capital Management LLC
1,698,165
1.46%
311,895
0.02%
06/30/2018
Dimensional Fund Advisors LP
1,653,862
1.43%
77,213
0.01%
06/30/2018
| Address |
149 Commonwealth Drive
Menlo Park California 94025
United States
|
|
Employees
|
- |
| Website |
http://www.corcept.com |
| Updated |
07/08/2019 |
| Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. |
